Related references
Note: Only part of the references are listed.
Article
Clinical Neurology
Emma C. Tallantyre et al.
Summary: The study found that some disease modifying therapies are associated with attenuated serological responses to SARS-CoV-2 vaccination in people with multiple sclerosis, including anti-CD20 monoclonal antibodies and fingolimod treatment. Additionally, vaccine type and treatment duration also impact vaccine response.
ANNALS OF NEUROLOGY
(2022)
Article
Immunology
Martin J. Scurr et al.
Summary: Accurate assessment of SARS-CoV-2 immunity is crucial, with T-cell responses being a key feature for protection. A high-throughput assay was developed to determine T-cell responses, showing significant differences in previously infected individuals and vaccination recipients. IFN-gamma was more effective in identifying asymptomatic donors, but IL-2 had higher specificity in healthy donors.
Article
Clinical Neurology
Afagh Garjani et al.
Summary: This study investigated the changes in SARS-CoV-2 infection risk among patients receiving disease-modifying therapies for multiple sclerosis (MS) after vaccination. The results showed that patients taking ocrelizumab or fingolimod had a lower level of protection from the SARS-CoV-2 vaccines compared to the general population.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Article
Medicine, General & Internal
Maria Pia Sormani et al.
Summary: This study aimed to monitor the risk of breakthrough SARS-CoV-2 infection in patients with MS under different DMTs and identify correlates of reduced protection. The results showed that reduced levels of virus-specific humoral immune response were associated with an increased risk of breakthrough infection.
Article
Biochemical Research Methods
Theodore T. Zava et al.
Summary: The study validated the feasibility of using DBS samples for Coronavirus disease 2019 IgG antibody testing, showing comparable accuracy and reliability to serum samples with minimal kit modifications needed.
Article
Medicine, General & Internal
Alasdair P S Munro et al.
Article
Clinical Neurology
Steve Simpson-Yap et al.
Summary: Using data from 12 sources in 28 countries, this study examined the characteristics of COVID-19 severity in people with MS, particularly those taking immunosuppressive therapies. The results showed that older age, progressive MS phenotype, and higher disability were associated with worse COVID-19 outcomes. Additionally, rituximab was consistently associated with increased risk of hospitalization, ICU admission, and need for ventilation, while ocrelizumab was mainly associated with hospitalization and ICU admission.
Article
Multidisciplinary Sciences
Pengfei Wang et al.
Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.
Article
Multidisciplinary Sciences
Zijun Wang et al.
Summary: Volunteers who received the Moderna or Pfizer-BioNTech vaccine showed high levels of antibodies and memory B cell responses against SARS-CoV-2, with activity similar to individuals who had recovered from natural infection. However, their efficacy against specific SARS-CoV-2 variants was reduced, indicating a potential need for periodic updates to mRNA vaccines to maintain clinical efficacy.
Article
Medicine, General & Internal
Sachin P. Gadani et al.
Summary: This study found robust T cell responses in individuals with multiple sclerosis on anti-CD20 therapies despite a reduced humoral response to SARS-CoV-2 vaccination. Follow-up studies are needed to determine if this translates to protection against COVID-19 infection.
Article
Biochemistry & Molecular Biology
Sokratis A. Apostolidis et al.
Summary: Patients with multiple sclerosis on anti-CD20 monotherapy exhibit significantly reduced SARS-CoV-2-specific antibodies and memory B cells, while CD4(+) and CD8(+) T cells are robustly activated compared to healthy controls after receiving BNT162b2 or mRNA-1273 mRNA vaccination.
Article
Clinical Neurology
Livnat Brill et al.
Summary: Patients with MS treated with ocrelizumab showed comparable SARS-CoV-2-specific T-cell responses with healthy controls but lower antibody response following vaccination. This study provides reassurance regarding the potential role of T cells in protection from severe disease and will aid in the development of consensus guidelines for MS treatment during the COVID-19 pandemic.
Article
Clinical Neurology
Maria Pia Sormani et al.
Summary: This study evaluated the impact of disease-modifying therapies on Covid-19 severity in patients with multiple sclerosis through a pooled-analysis of two large cohorts. The results showed that anti-CD20 therapies were significantly associated with severe Covid-19, while interferon indicated a decreased risk.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
(2021)
Article
Multidisciplinary Sciences
Klara Asplund Hogelin et al.
Summary: Research showed that almost all seropositive patients and 17.9% of seronegative patients on B cell depleting therapies developed anti-SARS-CoV-2 T cell memory, with functional similarity to controls. Following vaccination, vaccine-specific humoral memory was impaired, but all patients developed a specific T cell response.
Article
Cell Biology
Alison Tarke et al.
Summary: The study showed that SARS-CoV-2 variants do not significantly disrupt total T cell reactivity, although decreases in response frequency of 10%-22% were observed under certain assay/VOC combinations. This underscores the importance of actively monitoring T cell responses in the context of SARS-CoV-2 evolution.
CELL REPORTS MEDICINE
(2021)
Review
Immunology
Stanley A. Plotkin
CLINICAL AND VACCINE IMMUNOLOGY
(2010)
